Vaccine Adjuvant Research Programs

NIAID plays a leading role in the discovery, development, and characterization of new vaccine adjuvants that may be used to: improve the efficacy of current vaccines; design new or improved vaccines for existing and emerging infectious diseases; and develop vaccines to treat allergies, autoimmune diseases, and cancer.

Areas of Adjuvant Research

A scientist looking through a microscope

Adjuvant Discovery and Mechanistic Research

Discovery and Mechanistic Research seeks to identify novel adjuvant candidates that can be used to augment the efficacy of human vaccines and elucidate the immune mechanism of novel receptors.

heat map

Adjuvant Comparison

Adjuvant Comparison programs support the side-by-side comparison of experimental vaccines formulated with different adjuvants, to include comprehensive assessments of the strength, quality, breadth, and durability of immune responses.

Vile of vaccines

Adjuvant Development

Adjuvant Development supports the preclinical development of novel adjuvants for use in vaccines targeting immune-mediated or infectious diseases. 

A clinical trial participant getting a vaccine

Clinical Evaluation

This program is intended to address the limited availability of adjuvants that mimic those with a favorable clinical track record or show high potential in late pre-clinical testing.

Vaccine Adjuvant Compendium (VAC)

The Vaccine Adjuvant Compendium (VAC) was launched in 2021 by the NIAID Division of Allergy, Immunology, and Transplantation (DAIT) to foster collaborations between NIAID-supported adjuvant researchers and the broader scientific community.

Read more about VAC

Adjuvant Webinar Series

The NIAID Adjuvant Webinar Series presents current research relating to vaccine adjuvants on the fourth Tuesday of every month from 12:30 – 1:30 p.m. (ET) .

Read more and find out how to attend the Adjuvant Webinar Series

Contact Information

Points of contact for each program can be found on individual program pages.

Content last reviewed on